Texas Paid Clinical Trials

The purpose of this study is to map the acute, short-term cortical evoked responses to thalamic electrical stimulation in persons with intractable epilepsy Read Less

The purpose of this study is to study the long term safety and effectiveness of an artificial iris prosthesis for the treatment of iris defects. Read Less

A post-market registry evaluating the EmboTrap® Revascularization Device and CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion. Read Less

This is a multi-center, randomized, double-masked clinical trial. All study devices are market approved/cleared in the localities where the study is conducted. Subjects will be randomly assigned to wear NaturalVue Sphere single vision contact lenses (SVCL) or NaturalVue Multifocal (NVMF) soft contact lenses for a total of three years. Read Less

RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to: 1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. 2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes. 3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes. Read Less

eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized controlled trial of long-term (one year) prevention with eRapa versus placebo. The primary hypothesis is that eRapa decreases the risk of cancer relapse for patients with NMIBC. Secondary hypotheses are that eRapa can improve certain immune parameters and improve cognition and physical function without adversely affecting patient-reported outcomes and quality of life. Read Less

This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc. Read Less

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3 Read Less

Horizon Outreach has developed the Horizon Eagle Fatherhood Program (HEFP). HEFP includes a program/services aspect, but also includes a rigorous evaluation component, featuring a randomized control trial (RCT) research design. The evaluation will determine the effect of the Horizon Eagle Fatherhood Program with fathers aged 18 and up in Houston, Texas. Specifically, the research is examining the effects of the program relative to: (1) improvement in healthy relationship and marriage skills, (2) improvement in parenting skills, (3) improvement in conflict resolution and anger management skills, and (4) improvement in financial management skills and progress toward greater economic stability. Program participants will be randomly assigned to either the intervention group or the control group. Participants assigned to the intervention group will receive the program now. Participants assigned to the control group will have an opportunity to receive the program later. All participants (intervention and control) will complete a pretest questionnaire. Intervention participants will then participate in the Horizon Eagle Fatherhood program. This is an intensive 40-hour classroom-based program taught by project staff. Both intervention and control participants will receive case management services. Following completion of the program by the intervention participants, all participants will complete a posttest questionnaire. After completion of the posttest, all participants will have an opportunity to participate in a workforce training program. Six months following posttest, all participants will complete a third questionnaire. In addition, a selected number of participants will participate in focus groups. After completing the six-month follow-up questionnaire, participants from the control group may participate in the 40 hours of classroom instruction, should they choose to do so. This RCT research design component of the Horizon Eagle Fatherhood Program began in June of the second project year. Prior to the start of the RCT, a pilot/readiness project with no control group was conducted. This was followed by a short-term pilot of the RCT. Read Less

The purpose of this study is to characterize the safety and tolerability of FWD1509 MsOH in advanced NSCLC patients and establish the maximum tolerable dose (MTD), recommended phase 2 dose (RP2D) in advanced NSCLC patients. Read Less

A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers. Read Less

The purpose of this study is to clinically evaluate the effects of a school-based behavioral intervention, CATCH Healthy Smiles, to reduce the risk of dental caries in a cohort of kindergarten through 2nd grade (K-2) children serving low-income, ethnically-diverse children,to determine the impact of CATCH Healthy Smiles on child behavioral, psychosocial, and environmental outcomes beginning in K through 2nd grade, compared to children in the control schools and to examine the extent to which the child behavioral, psychosocial, and environmental factors mediate the improvements in child caries risk. Read Less